scholarly journals Treatment and prognosis of patients with urinary bladder cancer with other primary cancers: a nationwide population-based study in the Bladder Cancer Data Base Sweden (BladderBaSe)

2020 ◽  
Vol 126 (5) ◽  
pp. 625-632
Author(s):  
Firas Aljabery ◽  
Fredrik Liedberg ◽  
Christel Häggström ◽  
Viveka Ströck ◽  
Abolfazl Hosseini ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Urinary Bladder ◽  
Data Base ◽  
Urinary Bladder Cancer ◽  
Population Based ◽  
Population Based Study ◽  
Cancer Data

scholarly journals Cohort profile: The Swedish National Register of Urinary Bladder Cancer (SNRUBC) and the Bladder Cancer Data Base Sweden (BladderBaSe)

BMJ Open ◽  
2017 ◽  
Vol 7 (9) ◽  
pp. e016606 ◽  
Author(s):  
Christel Häggström ◽  
Fredrik Liedberg ◽  
Oskar Hagberg ◽  
Firas Aljabery ◽  
Viveka Ströck ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Urinary Bladder ◽  
Data Base ◽  
Cancer Survival ◽  
Urinary Bladder Cancer ◽  
Remote Access ◽  
National Register ◽  
Cancer Data ◽  
Muscle Invasive

PurposeTo monitor the quality of bladder cancer care, the Swedish National Register of Urinary Bladder Cancer (SNRUBC) was initiated in 1997. During 2015, in order to study trends in incidence, effects of treatment and survival of men and women with bladder cancer, we linked the SNRUBC to other national healthcare and demographic registers and constructed the Bladder Cancer Data Base Sweden (BladderBaSe).ParticipantsThe SNRUBC is a nationwide register with detailed information on 97% of bladder cancer cases in Sweden as compared with the Swedish Cancer Register. Participants in the SNRUBC have registered data on tumour characteristics at diagnosis, and for 98% of these treatment data have been captured. From 2009, the SNRUBC holds data on 88% of eligible participants for follow-up 5 years after diagnosis of non-muscle invasive bladder cancer, and from 2011, data on surgery details and complications for 85% of participants treated with radical cystectomy. The BladderBaSe includes all data in the SNRUBC from 1997 to 2014, and additional covariates and follow-up data from linked national register sources on comorbidity, socioeconomic factors, detailed information on readmissions and treatment side effects, and causes of death.Findings to dateStudies based on data in the SNRUBC have shown inequalities in survival and treatment indication by gender, regions and hospital volume. The BladderBaSe includes 38 658 participants registered in SNRUBC with bladder cancer diagnosed from 1 January 1997 to 31 December 2014. The BladderBaSe initiators are currently in collaboration with researchers from the SNRUBC investigating different aspects of bladder cancer survival.Future plansThe SNRUBC and the BladderBaSe project are open for collaborations with national and international research teams. Collaborators can submit proposals for studies and study files can be uploaded to servers for remote access and analysis. For more information, please contact the corresponding author.

Small cell carcinoma of the pancreas: population-based study of a rare tumor using the National Cancer Data Base

2015 ◽  
Vol 221 (4) ◽  
pp. e22
Author(s):  
Tommy Ivanics ◽  
John R. Bergquist ◽  
Christopher Shubert ◽  
Elizabeth B. Habermann ◽  
Rory L. Smoot ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Data Base ◽  
Small Cell Carcinoma ◽  
Population Based ◽  
National Cancer Data Base ◽  
Small Cell ◽  
Rare Tumor ◽  
Population Based Study ◽  
Carcinoma Of The Pancreas ◽  
Cancer Data

scholarly journals Survival of patients with urinary bladder cancer in Jordan, 2005–2014

2021 ◽  
Vol 27 (07) ◽  
pp. 648-655
Author(s):  
Nour Abdo ◽  
Majd Alsoukhni ◽  
Anwar Batieha ◽  
Kamal Arqoub
Keyword(s):  
Overall Survival ◽  
Bladder Cancer ◽  
Urinary Bladder ◽  
National Level ◽  
Urinary Bladder Cancer ◽  
Developed Countries ◽  
Cancer Data ◽  
Factors Associated ◽  
Survival Probabilities ◽  
Significant Difference

Background: Urinary bladder cancer is the fourth most common cancer in Jordan. No research on survival from bladder cancer at the national level has been conducted before. Aims: This study aimed to estimate the probability of survival in patients with bladder cancer in Jordan and identify factors associated with survival. Methods: Data were obtained from the database of the Jordan cancer registry. All cases of urinary bladder cancer in Jordanians registered during 2005–2014 were included in the study (n = 2139). Data collected for each case included: age, sex, date of diagnosis, and stage and grade at diagnosis. Actuarial life table survival analysis was used to determine the overall survival probabilities. Cox proportional hazard regression was used to identify independent factors associated with survival. Results: The overall 1-, 3-, 5- and 10-year survival probabilities for urinary bladder cancer were 85%, 73%, 69% and 59%, respectively (standard error = 0.01 for each). No significant difference in survival probabilities was found between males and females (P = 0.642). The overall survival probabilities decreased significantly as age at diagnosis increased (P < 0.005). Better survival was observed in patients with early stage and well differentiated tumours at diagnosis. Conclusions: The survival of patients with bladder cancer in Jordan is comparable to that reported from developed countries. A high percentage of data was missing and the reporting of some variables was inconsistent. To improve the quality of cancer data, regular training is needed for hospital focal points on recording complete data

scholarly journals Thromboembolism in Muscle-Invasive Bladder Cancer. A Population-based Nationwide Study

2021 ◽  
pp. 1-11
Author(s):  
Staffan Jahnson ◽  
Truls Gårdmark ◽  
Abolfazl Hosseini ◽  
Tomas Jerlström ◽  
Fredrik Liedberg ◽  
...  
Keyword(s):  
Risk Factors ◽  
Bladder Cancer ◽  
Cumulative Incidence ◽  
Cox Regression ◽  
Clinical Stage ◽  
Urinary Bladder Cancer ◽  
Population Based ◽  
Vte Prophylaxis ◽  
Cancer Data ◽  
Muscle Invasive

BACKGROUND: Routine VTE prophylaxis within 30 days of radical cystectomy (RC) for urinary bladder cancer (UBC) is used to protect from venous thromboembolism (VTE). However, randomized studies and nationwide population-based studies are lacking. OBJECTIVE: To study VTE and risk factors for VTE in muscle-invasive UBC in a nationwide population-based series, with a focus on the association with RC with and without chemotherapy. MATERIALS AND METHODS: We studied all patients with clinical stage T2-T4 UBC diagnosed 1997 to 2014 in the Bladder Cancer Data Base Sweden (BladderBaSe). Previous VTE events and risk factors for VTE were registered from 1987. Cox regression analyses and Kaplan-Meier curves were performed to study risk factors for VTE and cumulative incidence of VTE. RESULTS: In 9720 patients (71%males) with a median age of 74 years 546 (5.6%) had VTE after diagnosis. In Cox analyses controlling for patient’s and tumour characteristics, and risk factors for VTE, VTE after diagnosis and first treatment date were associated with chemotherapy with or without RC. Cumulative incidence of VTE increased during 24 months after diagnosis and first treatment date. VTE were less common in patients with previous cardiovascular disease. CONCLUSIONS: VTE was commonly observed after 30 days from diagnosis and from first treatment date in patients with T2-T4 UBC, particularly after chemotherapy. The findings suggest that long-term intervention studies of benefit and possible harms of VTE prophylaxis after UBC should be undertaken.

Sign in / Sign up

Export Citation Format

Share Document